Regeneron (REGN) Misses Q4 EPS by 48c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Roth Affirms Regeneron (REGN) at 'Buy' Following Q4 Results; Sees Opportunity in Shares on Pullback
February 10, 2016 11:53 AM ESTRoth Capital reaffirmed Regeneron (Nasdaq: REGN) at Buy with a price target of $555 after the company reported Q4 EPS of $2.83 and revenue of $1.1 billion, versus consensus estimates calling for EPS of $3.31 and revenue of $1.17 billion, this week.
Analyst Joseph Pantginis commented: REGN's shares have not been immune to the enhanced market turbulence surrounding... More
Leerink Partners Cuts Price Target on Regeneron (REGN) as Eylea Growth Slows
February 10, 2016 8:30 AM ESTLeerink Partners maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and cut the price target to $505.00 (from $534.00), following the company's 4Q earnings report. REGN reported weaker than expected 4Q results with soft Eylea growth and guidance, and lower total revenue and pro forma EPS. Regenerons Q4 Eylea revenue had been previously... More
Baird Cuts Price Target on Regeneron (REGN) as Late Stage Trials Hit Operating Costs - Reiterates Outperform
February 9, 2016 1:45 PM ESTBaird maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and cut the price target to $526.00 (from $674.00), following the company's 4Q. Non-GAAP EPS missed consensus at $2.81 compared to $3.38. Revenues were lower than expected at $1.10B versus consensus estimates of $1.17B. Mirroring REGN's pre-release in January, U.S.... More
